size. In cases of Tis, T1mi in T stage, and adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) in histological type, the CVs were larger than others. The comparison of radiological and pathological T stage, the accurate staging rate was 41.8%, and upstage were seen in 28.8% in all cases. Conclusion: Interobserver measurement variability of solid size of the lung adenocarcinoma was larger than those of total size. The difference between radiological and pathological invasion size tend to be larger in small-sized tumor as Tis and T1mi, and low-grade malignant potential lesions as AIS and MIA. Therefore, a careful consideration must be given to decide the management plan of these cases.
Background: Survivors of lung cancer (LC) have a high risk of developing second primary lung cancer(SPLC), the incidence of which is 4-6 times higher than that of initial primary lung cancer(IPLC). While national lung screening guidelines have been established for IPLC, no consensus guidelines exist for LC survivors. Furthermore, the factors that contribute to SPLC risk have not yet been established. The purpose of this study is to examine the potential of metabolomics to identify non-invasive blood-based biomarkers for SPLC screening. Method: We applied an untargeted metabolomics approach based on a liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) method to discover metabolic biomarkers using blood serum samples from the Boston Lung Cancer Study. Our study cohort consisted of 177 subjects diagnosed with IPLC between 1992 and 2012 and who survived >¼5 years after the initial diagnosis. The cohort included 82 SPLC cases and 95 matched controls (i.e. IPLC patients without SPLC as of Dec, 2017) based on the age of initial diagnosis, sex, race, and smoking status. We applied random forest and Welch's t-test to identify metabolomic features associated with SPLC risk and to build a risk prediction model. Result: Our analysis detected 1008 named and 316 unnamed metabolites. The metabolites that were statistically significantly associated with SPLC risk (False Discovery Rate q-value<0.05) included 5-methylthioadenosine (MTA), phenylacetylglutamine, and umbelliferone sulfate, which showed 1.4-3.8 fold increases among SPLC cases versus controls ( Figure 1) . These metabolites were involved in amino acid, peptide, and xenobiotics pathways. The stratification by quintiles of estimated risk using the prediction model based on the metabolites showed that the observed incidence of SPLC was significantly higher in the fifth quintile(69.4%) versus the first-quintile(36.1%;P<0.05). Background: In incidence lung cancer screening rounds, new lung nodules are a regular finding, with a higher lung cancer probability than baseline nodules. A substantial number of screen-detected nodules is classified as perifissural nodule (PFN). Previous studies showed that baseline PFNs and PFNs in clinical settings represent non-malignant lesions such as intrapulmonary lymph nodes. Whether this is also the case for incident PFNs is unknown. This study evaluates all newly detected nodules in the Dutch-Belgian randomized-controlled NELSON study with respect to perifissural classification and lung cancer probability. Method: All NELSON participants with a new solid nodule detected in screening round 2, 3 or 4 (1, 3, and 5.5 years after baseline, respectively), were enrolled in this substudy. Nodules were classified into three groups: intraparenchymal, vessel attached or fissure attached. Screening CT scans of participants with lung cancer based on a nodule classified as fissure attached, were re-evaluated by two radiologists (4 and 6 years of experience) to check whether this nodule was a typical, atypical or non-PFN. The fissure-attached cancers were matched based on size with benign cases (1:4), and the radiologists were blinded for the final nodule outcome. In case of discrepancy, a third radiologist (13 years of experience) arbitered. Result: 1,484 new nodules were detected in the second, third and final NELSON screening round in 949 participants (77.4% male, median age 59 [interquartile range: 55-63]). 1,393 nodules (93.8%) were benign based on 2 year follow-up or pathology; 96 of these (6.9%) were fissure attached. Lung cancer diagnosis was made in 74 new nodules in 74 participants (7.8% of participants with a new nodule). Nine lung cancers (12.1%) were fissure attached and re-evaluated by the radiologists. None of the fissure attached malignant new nodules was classified as a typical or atypical PFN. Conclusion: None of the lung cancers that originated from a new nodule in the NELSON study was classified as a typical or atypical PFN. Our results suggest that also in the case of a new PFN, it is highly unlikely that these PFNs will be diagnosed as lung cancer. Keywords: Lung cancer probability, lung nodule, lung cancer screening
